[1]
Carmeliet, P.; Jain, R.K. Angiogenesis in cancer and other diseases. Nature, 2000, 407, 249-257.
[2]
La Montagne, K.R.; Butler, J.; Borowski, V.B.; Fuentes-Pesquera, A.R.; Blevitt, J.M.; Huang, S.; Li, R.; Connolly, P.J.; Greenberger, L.M. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo. Angiogenesis, 2009, 12, 287-296.
[3]
Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86, 353-364.
[4]
Risau, W. Mechanisms of angiogenesis. Nature, 1997, 386, 671-674.
[5]
Ugale, V.G.; Patel, H.M.; Surana, S.J. Molecular modeling studies of quinoline derivatives as VEGFR-2 tyrosine kinase inhibitors using pharmacophore based 3D QSAR and docking approach. Arab. J. Chem., 2017, 10, S1980-S2003.
[6]
Musumeci, F.; Radi, M.; Brullo, C.; Schenone, S. Vascular Endothelial Growth Factor (VEGF) receptors: Drugs and new inhibitors. J. Med. Chem., 2012, 55, 10797-10822.
[7]
Dai, Y.; Guo, Y.; Frey, R.R.; Ji, Z.; Curtin, M.L.; Ahmed, A.A.; Albert, D.H.; Arnold, L.; Arries, S.S.; Barlozzari, T.; Bauch, J.L.; Bouska, J.J.; Bousquet, P.F.; Cunha, G.A.; Glaser, K.B.; Guo, J.; Li, J.; Marcotte, P.A.; Marsh, K.C.; Moskey, M.D.; Pease, L.J.; Stewart, K.D.; Stoll, V.S.; Tapang, P.; Wishart, N.; Davidsen, S.K.; Michaelides, M.R. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J. Med. Chem., 2005, 48, 6066-6083.
[8]
Hodous, B.L.; Geuns-Meyer, S.D.; Hughes, P.E.; Albrecht, B.K.; Bellon, S.; Caenepeel, S.; Cee, V.J.; Chaffee, S.C.; Emery, M.; Fretland, J.; Gallant, P.; Gu, Y.; Johnson, R.E.; Kim, J.L.; Long, A.M.; Morrison, M.; Olivieri, P.R.; Patel, V.F.; Polverino, A.; Rose, P.; Wang, L.; Zhao, H. Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 2886-2889.
[9]
Oguro, Y.; Miyamoto, N.; Okada, K.; Takagi, T.; Iwata, H.; Awazu, Y.; Miki, H.; Hori, A.; Kamiyama, K.; Imamura, S. Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo [3,2-d]pyrimidine derivatives: Novel VEGFR2 kinase inhibitors binding to inactive kinase conformation. Bioorg. Med. Chem., 2010, 18, 7260-7273.
[10]
Gangjee, A.; Kurup, S.; Ihnat, M.A.; Thorpe, J.E.; Shenoy, S.S. Synthesis and biological activity of N-4-phenylsubstituted-6-(2,4-dichlorophenylmethyl)-7H-pyrrolo[2,3-d] pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents. Bioorg. Med. Chem., 2010, 18, 3575-3587.
[11]
Egert-Schmidt, A.M.; Dreher, J.; Dunkel, U.; Kohfeld, S.; Preu, L.; Weber, H.; Ehlert, J.E.; Mutschler, B.; Totzke, F.; Schächtele, C.; Kubbutat, M.H.G.; Baumann, K.; Kunick, C. Identification of 2-anilino-9-methoxy-5,7-dihydro-6 H -pyrimido[5,4- d ][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation. J. Med. Chem., 2010, 53, 2433-2442.
[12]
Hughes, T.V.; Emanuel, S.L.; Beck, A.K.; Wetter, S.K.; Connolly, P.J.; Karnachi, P.; Reuman, M.; Seraj, J.; Fuentes-Pesquera, A.R.; Gruninger, R.H.; Middleton, S.A.; Lin, R.; Davis, J.M.; Moffat, D.F.C. 4-Aryl-5-cyano-2-aminopyrimidines as VEGFR-2 inhibitors: Synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2007, 17, 3266-3270.
[13]
Gaudette, F.; Raeppel, S.; Nguyen, H.; Beaulieu, N.; Beaulieu, C.; Dupont, I.; Macleod, A.R.; Besterman, J.M.; Vaisburg, A. Identification of potent and selective VEGFR receptor tyrosine kinase inhibitors having new amide isostere headgroups. Bioorg. Med. Chem. Lett., 2010, 20, 848-852.
[14]
Harris, P.A.; Boloor, A.; Cheung, M.; Kumar, R.; Crosby, R.M.; Davis-Ward, R.G.; Epperly, A.H.; Hinkle, K.W.; Hunter, R.N.; Johnson, J.H.; Knick, V.B.; Laudeman, C.P.; Luttrell, D.K.; Mook, R.A.; Nolte, R.T.; Rudolph, S.K.; Szewczyk, J.R.; Truesdale, A.T.; Veal, J.M.; Wang, L.; Stafford, J.A. Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem., 2008, 51, 4632-4640.
[15]
Prashantha Kumar, B.R.; Sankar, G.; Nasir Baig, R.B.; Chandrashekaran, S. Novel biginelli dihydropyrimidines with potential anticancer activity: A parallel synthesis and CoMSIA study. Eur. J. Med. Chem., 2009, 44, 4192-4198.
[16]
Tale, R.H.; Rodge, A.H.; Hatnapure, G.D.; Keche, A.P.; Patil, K.M.; Pawar, R.P. The synthesis, anti-inflammatory and antimicrobial activity evaluation of novel thioanalogs of 3,4-dihydrothiopyrimidin-2(1H)-one derivatives of N-aryl urea. Med. Chem. Res., 2012, 21, 4252-4260.
[17]
Sedaghati, B.; Fassihi, A.; Arbabi, S.; Ranjbar, M.; Memarian, H.R.; Saghaie, L.; Omidi, A.; Sardari, A.; Jalali, M.; Abedi, D. Synthesis and antimicrobial activity of novel derivatives of Biginelli pyrimidines. Med. Chem. Res., 2012, 21, 3973-3983.
[18]
Tale, R.H.; Rodge, A.H.; Hatnapure, G.D.; Keche, A.P. The novel 3,4-dihydropyrimidin-2(1H)-one urea derivatives of N-aryl urea: Synthesis, anti-inflammatory, antibacterial and antifungal activity evaluation. Bioorg. Med. Chem. Lett., 2011, 21, 4648-4651.
[19]
Jalali, M.; Mahdavi, M.; Memarian, H.R.; Ranjbar, M.; Soleymani, M.; Fassihi, A.; Abedi, D. Antimicrobial evaluation of some novel derivatives of 3,4-dihydropyrimidine-2(1H)-one. Res. Pharm. Sci., 2012, 7, 243-247.
[20]
Chiang, A.N.; Valderramos, J.C.; Balachandran, R.; Chovatiya, R.J.; Mead, B.P.; Schneider, C.; Bell, S.L.; Klein, M.G.; Huryn, D.M.; Chen, X.S.; Day, B.W.; Fidock, D.A.; Wipf, P.; Brodsky, J.L. Select pyrimidinones inhibit the propagation of the malarial parasite, Plasmodium falciparum. Bioorg. Med. Chem., 2009, 17, 1527-1533.
[21]
Trivedi, A.R.; Bhuva, V.R.; Dholariya, B.H.; Dodiya, D.K.; Kataria, V.B.; Shah, V.H. Novel dihydropyrimidines as a potential new class of antitubercular agents. Bioorg. Med. Chem. Lett., 2010, 20, 6100-6102.
[22]
Priya, N.; Singh, P.; Bhatia, S.; Medhi, B.; Prasad, A.K.; Parmar, V.S.; Raj, H.G. Characterization of a unique dihydropyrimidinone, ethyl 4-(4′-heptanoyloxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-one-5- carboxylate, as an effective antithrombotic agent in a rat experimental model. J. Pharm. Pharmacol., 2011, 63, 1175-1185.
[23]
Alam, O.; Khan, S.A.; Siddiqui, N.; Ahsan, W.; Verma, S.P.; Gilani, S.J. Antihypertensive activity of newer 1,4-dihydro-5-pyrimidine carboxamides: Synthesis and pharmacological evaluation. Eur. J. Med. Chem., 2010, 45, 5113-5119.
[24]
Atwal, K.S.; Rovnyak, G.C.; Kimball, S.D.; Floyd, D.M.; Moreland, S.; Swanson, B.N.; Gougoutas, J.Z.; Schwartz, J.; Smillie, K.M.; Malley, M.F. Dihydropyrimidine calcium channel blockers. 2. 3-substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridines. J. Med. Chem., 1990, 33, 2629-2635.
[25]
Nagarathnam, D.; Miao, S.W.; Lagu, B.; Chiu, G.; Fang, J.; Murali Dhar, T.G.; Zhang, J.; Tyagarajan, S.; Marzabadi, M.R.; Zhang, F.; Wong, W.C.; Sun, W.; Tian, D.; Wetzel, J.M.; Forray, C.; Chang, R.S.L.; Broten, T.P.; Ransom, R.W.; Schorn, T.W.; Chen, T.B.; O’Malley, S.; Kling, P.; Schneck, K.; Bendesky, R.; Harrell, C.M.; Vyas, K.P.; Gluchowski, C. Design and synthesis of novel α 1 a adrenoceptor-selective antagonists. 1. Structure-activity relationship in dihydropyrimidinones. J. Med. Chem., 1999, 42, 4764-4777.
[26]
Barrow, J.C.; Nantermet, P.G.; Selnick, H.G.; Glass, K.L.; Rittle, K.E.; Gilbert, K.F.; Steele, T.G.; Homnick, C.F.; Freidinger, R.M.; Ransom, R.W.; Kling, P.; Reiss, D.; Broten, T.P.; Schorn, T.W.; Chang, R.S.; O’Malley, S.S.; Olah, T.V.; Ellis, J.D.; Barrish, A.; Kassahun, K.; Leppert, P.; Nagarathnam, D.; Forray, C. In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha (1A) receptor antagonists for the treatment of benign prostatic hyperplasia. J. Med. Chem., 2000, 43, 2703-2718.
[27]
Yoon, S.Y.; Choi, J.E.; Huh, J.W.; Hwang, O.; Lee, H.S.; Hong, H.N.; Kim, D. Monastrol, a selective inhibitor of the mitotic kinesin Eg5, induces a distinctive growth profile of dendrites and axons in primary cortical neuron cultures. Cell Motil. Cytoskeleton, 2005, 60, 181-190.
[28]
Maliga, Z.; Kapoor, T.M.; Mitchison, T.J. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5. Chem. Biol., 2002, 9, 989-996.
[29]
Guido, B.C.; Ramos, L.M.; Nolasco, D.O.; Nobrega, C.C.; Andrade, B.Y.G.; Pic-Taylor, A.; Neto, B.A.D.; Corrêa, J.R. Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features. BMC Cancer, 2015, 15, 283.
[30]
Matsuno, K.; Sawada, J.; Sugimoto, M.; Ogo, N.; Asai, A. Bis (hetero) aryl derivatives as unique kinesin spindle protein inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 1058-1061.
[31]
DeBonis, S.; Skoufias, D.A.; Indorato, R.L.; Liger, F.; Marquet, B.; Laggner, C.; Joseph, B.; Kozielski, F. Structure-activity relationship of S-trityl-l-cysteine analogues as inhibitors of the human mitotic kinesin Eg5. J. Med. Chem., 2008, 51, 1115-1125.
[32]
Romagnoli, R.; Baraldi, P.G.; Cruz-Lopez, O.; Lopez Cara, C.; Carrion, M.D.; Brancale, A.; Hamel, E.; Chen, L.; Bortolozzi, R.; Basso, G.; Viola, G. Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues. J. Med. Chem., 2010, 53, 4248-4258.
[33]
Al-Soud, Y.A.; Al-Masoudi, N.A.; Ferwanah, A.S. Synthesis and properties of new substituted 1,2,4-triazoles: Potential antitumor agents. Bioorg. Med. Chem., 2003, 11, 1701-1708.
[34]
Tiwari, A.; Gopalan Kutty, N.; Kumar, N.; Chaudhary, A.; Vasanth Raj, P.; Shenoy, R.; Mallikarjuna Rao, C. Synthesis and evaluation of selected 1,3,4-oxadiazole derivatives for in vitro cytotoxicity and in vivo anti-tumor activity. Cytotechnology, 2016, 68, 2553-2565.
[35]
Ahsan, M.; Choupra, A.; Sharma, R.; Jadav, S.; Hassan, M.; Bakht, M.; Padmaja, P.; Al-Tamimi, A.; Geesi, M. Rationale design, synthesis, cytotoxicity evaluation, and molecular docking studies of 1,3, 4-oxadiazole analogues. Anticancer. Agents Med. Chem., 2018, 18(1), 121-138.
[36]
Cocco, M.T.; Congiu, C.; Lilliu, V.; Onnis, V. Synthesis and in vitro antitumoral activity of new 3,5-dicyanopyridine derivatives. Bioorg. Med. Chem., 2007, 15, 1859-1867.
[37]
Zhang, H.Z.; Drewe, J.; Tseng, B.; Kasibhatla, S.; Cai, S.X. Discovery and SAR of indole-2-carboxylic acid benzylidene-hydrazides as a new series of potent apoptosis inducers using a cell-based HTS assay. Bioorg. Med. Chem., 2004, 12, 3649-3655.
[38]
Vicini, P.; Incerti, M.; Doytchinova, I.A.; La Colla, P.; Busonera, B.; Loddo, R. Synthesis and antiproliferative activity of benzo[d] isothiazole hydrazones. Eur. J. Med. Chem., 2006, 41, 624-632.
[39]
Hussain, H.T.; Osama, M.; Hussain, W. Thiazolidin and Thiazan-4-ones: Synthesis, conformational analysis, antimicrobial and cytotoxic activity. Int. J. Mod. Biol. Med, 2014, 5, 65-80.
[40]
Wang, F.; Yin, H.; Yue, C.; Cheng, S.; Hong, M. Syntheses, structural characterization, in vitro cytotoxicities and DNA-binding properties of triphenylantimony di(N-oxy phthalimide) and di(N-oxy succinimide) complexes. J. Organomet. Chem., 2013, 738, 35-40.
[41]
Aliabadi, A.; Mohammadi-Farani, A.; Seydi-Kangarshahi, S.; Ahmadi, F. Discovery of 2-(1,3-dioxoisoindolin-2-Yl)-N-phenyl-acetamide derivatives as probable 15-lipoxygenase-1 inhibitors with potential anticancer effects. Farmacia, 2017, 65, 268-274.
[42]
Mostafa, A.S.; El Bialy, S.A.; Bayoumi, W.A.; Abdelal, A.M. Synthesis and in vitro activity of novel non-nucleoside derivatives as anti-HCV agents. MJPS, 2012, 27, 1-10.
[43]
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 1983, 65(1-2), 55-63.
[44]
Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbel, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 1991, 83, 757-766.
[45]
Molecular Operating Environment (MOE), 2013.08; Chemical
Computing Group ULC, 1010 Sherbooke St. West, Suite #910,
Montreal, QC, Canada, H3A 2R7, 2017..
[46]
Slobbe, P.; Ruijter, E.; Orru, R.V.A. Recent applications of multicomponent reactions in medicinal chemistry. MedChemComm, 2012, 3, 1189-1218.
[47]
Singh, M.S.; Chowdhury, S. Recent developments in solvent-free multicomponent reactions: A perfect synergy for eco-compatible organic synthesis. RSC Adv, 2012, 2, 4547-4592.
[48]
Biginelli, P. Ueber aldehyduramide des acetessigäthers. Berichte Der Dtsch. Chem. Gesellschaft., 1891, 24, 1317-1319.
[49]
Kappe, C.O. 100 years of the blglnelll dihydropyrimidine synthesis. Tetrahedron, 1993, 49, 6937-6963.
[50]
Yu, Y.; Liu, D.; Liu, C.; Luo, G. One-pot synthesis of 3,4-dihydropyrimidin-2(1H)-ones using chloroacetic acid as catalyst. Bioorg. Med. Chem. Lett., 2007, 17, 3508-3510.
[51]
Denizot, F.; Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods, 1986, 89, 271-277.
[52]
Boyd, M.R.; Paull, K.D. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev. Res., 1995, 34, 91-109.
[53]
Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.; Boyd, M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 1990, 82, 1107-1112.
[54]
Grever, M.R.; Schepartz, S.A.; Chabner, B.A. The national cancer institute: Cancer drug discovery and development program. Semin. Oncol., 1992, 19, 622-638.
51
5
1